antimicrobi
properti
fatti
acid
extens
report
literatur
review
see
thormar
et
al
thormar
hilmarsson
churchward
et
al
previous
thormar
et
al
demonstr
antivir
effect
differ
free
fatti
acid
lipid
extract
human
milk
vesicular
stomat
viru
vsv
herp
simplex
viru
hsv
visna
viru
reveal
short
chain
satur
fatti
acid
butyr
caproic
capryl
togeth
long
chain
satur
fatti
acid
palmit
stearic
littl
antivir
activ
wherea
medium
chain
satur
entiti
includ
capric
lauric
myrist
long
chain
unsatur
oleic
linol
linolen
acid
antivir
albeit
differ
concentr
anoth
studi
hilmarsson
et
al
report
similar
trend
antivir
activ
six
medium
chain
fatti
acid
togeth
alcohol
monoglycerid
deriv
herp
simplex
virus
contrast
dichtelmul
et
al
report
capryl
acid
antivir
activ
envelop
virus
includ
human
immunodefici
viru
bovin
viral
diarrhoea
viru
sindbi
viru
pseudorabi
viru
dichtelmul
et
al
pingen
et
al
studi
investig
antivir
properti
whole
milk
report
antivir
properti
fresh
human
milk
wherea
milk
store
c
possess
potent
antivir
activ
sever
virus
vitro
refriger
disrupt
milk
fat
globul
membran
allow
ingress
milk
serum
lipas
result
hydrolysi
milk
fat
triglycerid
thormar
et
al
isaac
et
al
conclud
releas
fatti
acid
milk
triglycerid
store
milk
recov
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
neonat
achlorhydr
stomach
respons
gener
antivir
factor
thormar
et
al
investig
effect
specif
formul
emuls
free
fatti
acid
viros
infect
envelop
nonenvelop
virus
capryl
acid
deliv
viros
emuls
exhibit
signific
antivir
effect
rang
envelop
viral
infect
system
util
complet
inhibit
viral
infect
observ
without
evid
cytotox
viros
effect
infect
nonenvelop
viru
noroviru
agreement
previou
studi
demonstr
free
fatti
acid
ineffect
nonenvelop
virus
thormar
et
al
kohn
et
al
furthermor
viros
inactiv
envelop
mosquitoborn
virus
semliki
forest
viru
sfv
zika
viru
zikv
vitro
prophylact
topic
treatment
viral
infect
mosquito
bite
viros
inhibit
local
replic
dissemin
sfv
plasma
level
zikv
mice
transmiss
electron
microscopi
analysi
indic
viros
disrupt
orf
parapoxviru
envelop
integr
higher
concentr
complet
disrupt
virion
morpholog
data
indic
viros
antivir
activ
rang
envelop
virus
vitro
vivo
vero
cell
raw
murin
macrophag
human
embryon
kidney
cell
murin
microgli
cell
propag
dmem
supplement
fetal
bovin
serum
fb
mm
lglutamin
gibco
antibiot
penicillinml
streptomycinml
nonessenti
amino
acid
gibco
babi
hamster
cell
mosquito
cell
grown
previous
describ
pingen
et
al
vero
cell
engin
overexpress
signal
lymphocyt
activ
molecul
slam
supplement
geneticin
sigma
human
foreskin
fibroblast
cell
obtain
atcc
propag
dmem
supplement
fb
lglutamin
antibiot
penicillinml
streptomycinml
nonessenti
amino
acid
primari
tonsil
epitheli
cell
isol
normal
tonsil
tissu
obtain
hypophysectomi
previous
describ
feederl
et
al
primari
foetal
lamb
skin
fl
cell
isol
previous
describ
scagliarini
et
al
cultur
medium
heat
inactiv
fb
cell
maintain
c
gd
antibodi
gener
gift
colin
crump
univers
cambridg
minson
et
al
antimous
antibodi
obtain
gibco
uk
pseudovirus
gener
transfect
cell
plasmid
encod
proviru
express
luciferas
vesicular
stomat
viru
vsvg
zika
ebola
lassa
sar
envelop
envelop
control
env
previous
describ
fletcher
et
al
broer
et
al
zika
viru
pseudovirus
gener
amplifi
premmenv
region
posit
brazil
zika
strain
access
flank
restrict
site
insert
plasmid
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
viru
contain
media
incub
indic
concentr
viros
minut
room
temperatur
unless
state
otherwis
equal
concentr
neutral
buffer
ad
restor
ph
virusviros
solut
ad
target
cell
hour
prepar
viros
titrat
relev
media
use
cultur
cell
type
dmem
william
e
control
ph
treatment
viru
treat
buffer
contain
viros
minut
ph
restor
describ
viros
treatment
viru
ad
target
cell
hour
unbound
viru
remov
media
replac
fb
postinfect
cell
lyse
luciferas
substrat
ad
promega
uk
luciferas
activ
measur
second
luminomet
lumat
specif
infect
calcul
subtract
mean
envpp
rlu
signal
pseudoviru
rlu
signal
infect
present
rel
untreat
control
cell
defin
mean
luciferas
valu
replic
untreat
cell
assess
cell
viabil
follow
viros
treatment
mtt
assay
perform
replic
well
everi
experi
gibco
uk
carri
open
read
frame
enhanc
green
fluoresc
protein
egfp
gener
describ
previous
hashimoto
et
al
initi
recoveri
mev
produc
veroslam
cell
use
initi
multipl
infect
infect
fulli
develop
flask
vigor
shaken
supernat
collect
clarifi
supernat
collect
aliquot
store
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
recombin
wildtyp
epsteinbarr
viru
ebv
gfp
insert
deleclus
et
al
gener
cell
carri
recombin
ebv
genom
previous
describ
shannonlow
et
al
encapsid
envelop
viru
purifi
cultur
supernat
centrifug
optiprep
axi
shield
selfgener
gradient
shannonlow
et
al
quantit
quantit
pcr
qpcr
singlecopi
gene
previous
describ
shannonlow
et
al
herp
simplex
viru
strain
propag
vero
cell
previous
describ
ren
et
al
titrat
perform
confluent
cultur
vero
cell
agaros
overlay
fc
infecti
titr
determin
plaqu
form
unit
pfu
vitro
work
zika
viru
brazil
propag
vero
cell
previous
describ
chavali
et
al
titrat
perform
confluent
cultur
vero
cell
agaros
overlay
fc
infecti
titr
quantifi
plaqu
form
unit
pfu
viru
stock
pool
titr
vero
cell
determin
valu
orf
viru
mriscab
propag
scarif
lamb
previous
describ
mcinn
et
al
cultur
infect
primari
foetal
lamb
skin
fl
cell
infect
experi
perform
direct
inocul
orf
viru
onto
primari
cultur
fl
cell
scagliarini
et
al
murin
noroviru
strain
propag
murin
raw
cell
wobu
et
al
yield
infecti
viru
determin
posttransfect
cdna
cap
rna
titr
viru
determin
tissu
cultur
infecti
dose
raw
cell
use
microscop
visual
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
appear
cytopath
effect
backbon
product
sfv
previous
describ
ulper
et
al
sfv
plasmid
electropor
cell
gener
infecti
viru
prototyp
less
virul
strain
viru
wherea
copi
virul
strain
ferguson
et
al
vivo
experi
sfv
zikv
brazil
virus
grown
cell
passag
aed
mosquito
cell
titrat
use
mosquito
cellderiv
viru
distinct
glycosyl
insect
cell
impos
distinct
evolutionari
constraint
viral
progeni
moser
et
al
use
passag
westgat
biomed
ltd
doneg
ireland
folan
patent
wo
compon
use
construct
viros
pharmaceut
grade
constitu
greater
puriti
viros
emuls
use
studi
construct
use
lipoid
lecithin
lipoid
ag
steinhausen
switzerland
ww
delipidis
use
solvent
extract
remov
extran
lipid
remain
conjug
lipophil
site
delipidis
lecithin
amphipath
cosurfact
pluron
basf
cork
ireland
use
enhanc
stabil
dipalmitoyl
sodium
salt
dppg
lipoid
ag
use
amplifi
surfac
charg
emuls
droplet
pharmaceut
grade
capryl
acid
merck
nottingham
uk
ww
emulsifi
delipidis
lecithin
pluron
dppg
mix
ww
ww
respect
use
emulsiflex
avestin
ottowa
canada
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
bar
pressur
emuls
dilut
ww
capryl
acid
use
concentr
specifi
experi
sodium
citrat
buffer
ph
physiolog
isoton
optim
cultur
medium
use
autoclav
use
laverti
et
al
topic
applic
mous
skin
gel
formul
construct
use
wv
carbopol
lubrizol
inc
cleveland
ohio
usa
dispers
hydrat
aqueou
solut
glycerol
merck
ph
adjust
addit
viros
emuls
gel
appli
liber
test
site
describ
viros
acid
ph
necessit
minim
time
exposur
cell
line
follow
neutral
buffer
restor
ph
studi
viros
indic
concentr
mix
equal
volum
viral
inoculum
mev
origin
ml
pfuml
ebv
zika
orf
pfuml
pseudovirus
bear
vsv
ebola
lassa
envelop
glycoprotein
incub
room
temperatur
minut
volum
buffer
neutral
solut
ad
mix
thoroughli
restor
ph
viros
neutral
solut
optim
cultur
medium
use
vitro
studi
control
effect
low
ph
infect
buffer
solut
ad
viru
incub
neutral
virusviros
control
treat
viru
inocul
onto
appropri
target
cell
incub
fix
infect
enumer
pseudoviru
assay
lyse
luciferas
activ
quantifi
previous
describ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
fletcher
et
al
mev
calcul
veroslam
cell
triplic
use
reedmuench
method
reed
nonenvelop
viral
infect
assay
similar
approach
use
envelop
viru
assay
viros
mix
murin
noroviru
ratio
incub
room
temperatur
minut
ph
restor
viru
infect
permiss
raw
mous
macrophag
murin
microgli
cell
conduct
immedi
neutral
triplic
incub
quantifi
post
infect
use
via
microscop
visual
appear
cytopath
effect
femal
mice
deriv
local
bred
coloni
maintain
pathogenfre
facil
filtertop
cage
maintain
accord
local
government
regul
prevent
genet
drift
mice
rederiv
use
extern
suppli
mice
charl
river
arboviru
infect
skin
alway
occur
context
arthropod
bite
use
mous
model
addit
incorpor
bite
aed
aegypti
mosquito
host
respons
mosquito
bite
includ
oedema
influx
leukocyt
enhanc
host
suscept
infect
viru
pingen
et
al
therefor
use
previous
establish
model
arboviru
infect
mosquito
bite
model
specif
develop
model
natur
infect
arboviru
includ
mimick
dose
deliv
mosquito
use
mosquito
cellderiv
viru
inject
small
inoculum
volum
includ
presenc
mosquito
bite
site
inocul
ensur
mosquito
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
bit
defin
area
skin
upper
side
left
foot
anesthet
mice
place
min
mosquito
cage
contain
aegypti
mosquito
local
bred
coloni
deriv
liverpool
strain
bite
restrict
defin
area
left
foot
cover
mous
skin
impenetr
barrier
viral
rna
host
gene
transcript
tissu
quantifi
revers
transcript
qpcr
infecti
viru
quantifi
end
point
titrat
describ
previous
tissu
gener
ug
total
rna
ug
rna
use
creat
cdna
use
per
qpcr
assay
qpcr
primer
sfv
amplifi
section
primer
zikv
amplifi
section
env
gene
sfv
zikv
qpcr
assay
measur
sum
valu
genom
subgenom
rna
bryden
et
al
result
repres
median
three
four
technic
replic
one
biolog
replic
plaqu
assay
viral
stock
biolog
sampl
serial
dilut
dilut
assay
duplic
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
avicel
overlay
hour
previous
describ
pingen
et
al
biolog
replic
mice
exclud
analysi
inject
viru
inadvert
punctur
blood
vessel
although
rare
occur
frequenc
experi
involv
mice
subject
rigor
review
univers
leed
welfar
ethic
review
committe
addit
approv
uk
home
offic
licens
zika
infect
cell
fix
paraformaldehyd
stain
primari
antizikaeprotein
antibodi
secondari
antimous
cell
resuspend
pb
cell
screen
flow
cytometri
use
facscalibur
flow
cytomet
bd
bioscienc
germani
data
analyz
use
flowjo
softwar
flowjo
llc
usa
orf
mriscab
harvest
supernat
primari
cultur
foetal
lamb
skin
fl
cell
filter
filter
centrifug
hour
benchtop
centrifug
eppendorf
viru
place
formvar
coat
copper
electron
microscopi
grid
minut
excess
supernat
remov
grid
stain
uranyl
acet
grid
visual
use
tecnai
transmiss
electron
microscop
vitro
result
express
mean
standard
deviat
mean
sd
except
state
statist
analys
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
perform
use
student
ttest
mannwhitney
u
test
prism
graphpad
san
diego
ca
p
consid
statist
signific
vivoderiv
data
data
analyz
use
graphpad
prism
version
softwar
copi
number
viral
rna
infecti
titr
virusinfect
mice
normal
distribut
data
point
often
spread
order
magnitud
accordingli
analyz
use
nonparametricbas
mannwhitney
test
kolmogorovsmirnov
test
assess
abil
viros
inhibit
viral
infect
util
pseudoviru
system
allow
high
throughput
assay
assess
viral
entri
cell
viros
inhibit
entri
viral
pseudoparticl
bear
envelop
glycoprotein
vsv
lassa
ebola
virus
pseudovir
particl
mirror
entri
pathway
respect
wild
type
virus
use
viral
receptor
entri
pathway
review
see
li
et
al
construct
gener
high
titr
pseudovirus
use
infect
rang
cell
type
inhibit
pseudoviru
entri
viros
occur
concentrationdepend
manner
pseudovirus
incub
viros
minut
figur
treatment
pseudovirus
viros
result
complet
neutral
pseudoviru
infect
human
embryon
kidney
cell
figur
alter
cellular
prolifer
cytotox
cell
treat
pseudoviru
viros
assess
use
mtt
assay
data
shown
viros
stabl
pseudoviru
treatment
carri
restor
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
infect
eukaryot
cell
treatment
vsv
lassa
pseudovirus
control
buffer
caus
signific
chang
infect
howev
signific
reduct
ebola
pseudoviru
infect
observ
figur
establish
whether
viros
inhibit
pseudoviru
infect
cell
type
virosaltr
lassa
vsv
pseudoparticl
use
infect
human
intestin
hepatoma
epitheli
cell
monolay
similar
level
neutral
viros
observ
compar
cell
inhibit
viral
infect
control
treatment
perhap
due
less
effici
entri
viral
pseudoparticl
cell
compar
highli
permiss
cell
line
supplementari
figur
mani
aspect
envelop
viru
lifecycl
ph
sensit
ruigrok
et
al
ph
common
variabl
assess
antimicrobi
activ
fatti
acid
churchward
et
al
case
control
viros
treatment
compar
expos
viru
ph
test
whether
viros
inhibit
pseudoviru
infect
follow
short
treatment
time
vsv
pseudovirus
incub
viros
concentr
minut
use
infect
cell
timedepend
decreas
infect
observ
figur
viros
inhibit
vsv
pseudoviru
concentr
greater
follow
second
treatment
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
test
whether
viros
capabl
inhibit
fulllength
infecti
virus
use
rang
infecti
viru
system
select
cell
cultur
system
pseudovirus
gener
bear
envelop
glycoprotein
zika
viru
strain
brazilian
strain
abil
viros
inhibit
pseudoviru
entri
togeth
fulllength
infecti
clone
zika
viru
strain
african
strain
compar
viros
inhibit
zika
viru
pseudoviru
similar
zika
viru
higher
concentr
viros
requir
complet
neutral
fulllength
virus
compar
pseudovirus
treatment
viros
result
cytotox
measur
use
mtt
assay
data
shown
indic
viros
capabl
fulli
neutral
rang
envelop
virus
vitro
concentr
caus
cytotox
eukaryot
cell
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sinc
viros
potent
inhibit
infect
rang
envelop
virus
sought
establish
whether
effect
limit
envelop
virus
whether
viros
also
influenc
nonenvelop
virus
murin
noroviru
nonenvelop
viru
treat
viros
ad
cultur
murin
macrophag
murin
microgli
cell
signific
differ
control
treat
viru
viros
treat
viru
infect
either
cell
type
test
figur
indic
contrast
viros
effect
envelop
virus
viros
inhibit
infect
noroviru
nonenvelop
viru
activ
investig
compon
viros
respons
activ
evalu
individu
compon
viros
capryl
dppg
lecithin
kolliphor
concentr
equival
amount
present
viros
togeth
viros
ifni
posit
antivir
control
capryl
capryl
acid
signific
effect
vsvg
pseudoviru
entri
vero
cell
figur
howev
viros
fulli
neutral
viral
entri
indic
capryl
acid
within
viros
formul
potent
antivir
capryl
acid
alon
examin
potenti
perturb
envelop
viru
membran
use
transmiss
electron
microscopi
visual
virosaltr
orf
virion
orf
parapoxviru
famili
virus
includ
pseudocowpox
bovin
papular
stomat
viru
select
larg
size
virion
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
diamet
rel
high
titr
achiev
follow
growth
cell
cultur
neg
stain
virion
exhibit
typic
poxviru
morpholog
figur
ovoid
structur
surround
extern
envelop
treatment
orf
virion
viros
neutral
approxim
infect
infect
assay
figur
appear
disrupt
extern
viral
envelop
remain
associ
virion
figur
treatment
viros
complet
neutral
vitro
infect
figur
disrupt
virion
morpholog
latticelik
structur
present
intact
virion
figur
data
indic
viros
disrupt
orf
surfac
structur
virion
morpholog
arbovirus
transmit
mammalian
host
via
bite
insect
vector
given
viros
optim
activ
slightli
acid
ph
seen
skin
mucos
surfac
investig
effect
viros
treatment
mous
skin
follow
viral
inocul
site
aed
aegypti
bite
accord
previous
publish
protocol
bryden
et
al
arboviru
replic
skin
mosquito
bite
key
stage
infect
viru
replic
rapidli
dissemin
blood
tissu
pingen
et
al
previou
work
suggest
therapeut
target
site
may
efficaci
reduc
sever
infect
bryden
et
al
zikv
chosen
medic
import
emerg
arboviru
wherea
sfv
use
model
viru
replic
effici
immunocompet
mice
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
firstli
show
viros
inactiv
infecti
sfv
vitro
supplementari
figur
addit
zikv
figur
incub
increas
infecti
titr
viros
minut
follow
immedi
restor
physiolog
ph
solut
appli
monolay
cell
infecti
titr
assess
plaqu
assay
control
incub
similarli
absenc
viros
amount
infecti
sfv
reduc
beyond
limit
detect
viros
suggest
viru
highli
sensit
treatment
supplementari
figur
similarli
viros
treat
inocul
subcutan
mice
titr
viru
hour
post
infect
significantli
reduc
supplementari
figur
next
determin
whether
topic
applic
viros
also
suppress
viru
infect
viru
inocul
subcutan
mosquito
bite
experi
viros
appli
immedi
post
mosquito
bite
left
minut
allow
penetr
skin
viros
left
untreat
control
sfv
inocul
subcutan
mosquito
bite
previous
describ
pingen
et
al
reapplic
viros
inocul
site
repeat
hour
post
infect
hour
post
infect
mice
receiv
viros
significantli
reduc
amount
viru
rna
inoculationbit
site
limit
dissemin
viru
spleen
hour
post
infect
figur
infecti
viral
titr
within
plasma
also
significantli
reduc
figur
topic
applic
viros
mosquito
bite
similarli
efficaci
reduc
zikv
serum
viraemia
hour
post
zikv
infect
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
viros
use
studi
proprietari
emuls
free
fatti
acid
previous
shown
antibacteri
properti
includ
rang
veterinari
periodontopathogen
laverti
et
al
staphylococcu
speci
includ
methicillinresist
staphylococcu
aureu
hogan
et
al
well
wide
rang
cultur
speci
human
colon
mcdermott
et
al
antimicrobi
activ
medium
chain
satur
long
chain
unsatur
free
fatti
acid
report
previous
thormar
hilmarsson
antibacteri
antivir
activ
observ
hilmarsson
et
al
capryl
acid
use
purif
process
immunoglobulin
due
inactiv
lipid
envelop
virus
dichtelmul
et
al
process
phdepend
optim
low
ph
poor
solubl
aqueou
solut
limit
antimicrobi
applic
fatti
acid
free
form
jackman
et
al
dissolut
solvent
dmso
caus
skin
irrit
formul
nanoparticl
describ
overcom
challeng
antimicrobi
fatti
acid
bioavail
jackman
et
al
yoon
et
al
studi
use
patent
technolog
folan
intern
patent
wo
build
use
emuls
evalu
antivir
potenti
recent
public
note
potenti
antimicrobi
activ
nanoemuls
microemuls
churchward
et
al
buranasuksombat
et
al
et
al
donsi
ferrari
studi
data
clearli
evalu
contribut
individu
compon
overal
properti
mix
system
may
synergist
antagonist
howev
compon
viros
gener
regard
safe
gra
unit
state
food
drug
administr
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antivir
activ
viros
emuls
may
due
amplifi
surfac
area
water
insolubl
fatti
acid
togeth
amphipath
natur
delipidis
lecithin
facilit
deliveri
lipophil
cell
surfac
andor
viral
envelop
laverti
et
al
observ
signific
concentrationand
timedepend
rapid
decreas
infect
envelop
virus
test
present
studi
effect
nonenvelop
noroviru
milkbas
free
fatti
acid
well
fatti
acid
emuls
shown
inhibit
infect
vero
cell
vsv
antivir
effect
polioviru
nonenvelop
viru
thormar
et
al
moreov
isaac
isaac
et
al
report
antivir
activ
human
milk
milk
formula
potent
antivir
activ
milk
aspir
stomach
infant
one
hour
feed
occur
due
releas
free
fatti
acid
lipolysi
similar
observ
report
thormar
et
al
thormar
et
al
lipolysi
storag
human
milk
follow
treatment
orf
viru
viros
observ
dissoci
viral
envelop
virion
higher
concentr
disrupt
virion
integr
morpholog
agreement
present
studi
fatti
acid
found
affect
viral
envelop
high
concentr
caus
complet
disintegr
viral
particl
thormar
et
al
thormar
et
al
agreement
present
studi
previou
studi
also
report
antivir
effect
fatti
acid
nonenvelop
virus
thormar
et
al
churchward
et
al
indic
antivir
mechan
free
fatti
acid
viros
may
involv
viral
envelop
anticip
due
surfact
effect
yoon
et
al
yoon
et
al
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
nonionis
form
capryl
acid
dissoci
basic
ph
ioniz
form
nonionis
form
capabl
viru
inactiv
lundblad
seng
viros
optim
activ
consequ
suitabl
use
environ
close
ph
skin
oral
caviti
mucou
membran
also
relev
portal
infect
present
studi
demonstr
viros
antivir
activ
ebv
orf
virus
pathogen
skin
mucou
membran
tropism
epitheli
cell
sinc
viros
optim
activ
also
test
rang
epitheli
cell
system
would
physiolog
lower
ph
plasma
skin
ph
approxim
lamber
et
al
oral
caviti
ph
lower
depend
level
oral
health
viros
strong
antivir
activ
semliki
forest
zika
virus
transmit
via
mosquito
skin
dermi
import
stage
viru
life
cycl
replic
dermal
cell
dissemin
blood
throughout
bodi
hamel
et
al
pingen
et
al
potenti
viros
topic
applic
immedi
follow
mosquito
bite
great
interest
establish
emerg
mosquitoborn
virus
constitut
increas
threat
human
health
treatment
modal
incorpor
viros
target
skin
arboviru
infect
explor
eg
treatment
mosquito
bite
inocul
site
immunomodul
recent
shown
effect
strategi
suppress
arboviru
infect
bryden
et
al
moreov
viros
also
neutral
measl
viru
pseudoviru
infect
measl
aerosol
transmit
infect
initi
target
macrophag
dendrit
cell
upper
airway
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
transport
across
respiratori
epithelium
lymphat
organ
muhlebach
et
al
similarli
caus
acut
interstiti
pneumonia
caus
agent
sar
coronaviru
epidem
viros
therefor
potenti
applic
topic
inhal
therapi
treat
epitheliotrop
viral
infect
infect
airway
mucou
membran
fact
viros
applic
wide
rang
envelop
virus
great
interest
mani
antivir
activ
specif
viral
famili
broadspectrum
antivir
current
avail
therefor
data
provid
rational
futur
preclin
studi
investig
antivir
properti
viros
viral
infect
mucou
membran
includ
airway
skin
viros
may
applic
current
futur
viral
outbreak
includ
current
pandem
caus
ebola
spike
protein
treat
dilut
concentr
viros
rang
final
concentr
rang
minut
buffer
ad
restor
ph
control
effect
ph
viral
infect
viru
treat
buffer
equival
viros
minut
ph
viru
restor
pseudovirus
use
infect
human
embryon
kidney
cell
ifni
includ
posit
antivir
control
data
present
mean
infect
sd
rel
untreat
viru
control
b
pseudoviru
bear
envelop
glycoprotein
vsv
treat
minut
viros
ph
restor
use
infect
cell
control
viru
treat
buffer
minut
ph
restor
statist
differ
present
rel
control
n
independ
experi
p
p
p
ns
signific
treat
rang
dilut
viros
minut
viral
load
quantifi
qrtpcr
c
zika
viru
treat
viros
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
use
infect
human
foreskin
cell
cell
stain
antiflaviviru
antibodi
isotyp
control
antimous
secondari
antibodi
infect
cell
quantifi
flow
cytometri
statist
differ
present
rel
control
n
independ
experi
p
p
infect
strain
treat
viros
minut
ph
restor
use
infect
vero
cell
control
viru
treat
buffer
minut
ph
restor
hour
cell
fix
stain
antibodi
detect
hsv
gd
glycoprotein
imag
shown
repres
phase
imag
b
measl
ebv
orf
viru
treat
viros
minut
ph
restor
use
infect
vero
primari
tonsil
epitheli
cell
primari
foetal
lamb
skin
cell
respect
control
viru
treat
buffer
minut
ph
restor
hour
viral
infect
enumer
data
present
neutral
infect
rel
untreat
viru
control
murin
noroviru
treat
viros
minut
ph
restor
use
infect
either
murin
macrophag
murin
microgli
cell
viral
infect
measur
quantifi
via
microscop
visual
signific
differ
observ
follow
viros
treatment
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
compar
control
treat
viru
b
vsvg
pseudoviru
treat
viros
equival
concentr
capryl
dppg
lecithin
kolliphor
minut
ph
restor
control
effect
ph
viral
infect
viru
treat
buffer
equival
viros
minut
ph
viru
restor
ifni
includ
posit
antivir
control
data
present
mean
infect
sd
rel
untreat
viru
control
n
independ
experi
p
p
ns
signific
orf
viru
mriscab
treat
buffer
viros
b
viros
c
minut
ph
restor
mock
treat
virion
exhibit
typic
poxviru
morpholog
promin
outer
envelop
virion
treat
low
concentr
viros
display
alter
morpholog
extern
envelop
integr
disrupt
arrow
b
virion
treat
high
concentr
viros
exhibit
heterogen
morpholog
extens
disrupt
virion
structur
arrow
follow
bite
aed
aegypti
mosquito
mous
foot
upper
side
skin
treat
topic
viros
follow
minut
allow
penetr
skin
viros
site
inocul
semliki
forest
viru
zika
viru
microneedl
inject
bite
site
retreat
viros
hour
post
inocul
mice
left
untreat
mice
hour
post
infect
anim
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
euthan
viral
load
skin
spleen
enumer
qrtpcr
b
c
infecti
viru
zika
infect
mice
enumer
plaqu
form
assay
pfu
hour
postinfect
p
p
p
mannwhitney
test
